Home  >  Press Releases  >  Most Recent
Share

Press Releases

Press release year list 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006
December 18, 2019
Zoetis Inc. (NYSE:ZTS) will participate in the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, 2020, in San Francisco, Calif. Kristin Peck, who will become Chief Executive Officer of Zoetis on January 1, 2020, will represent the company and respond to questions from analysts. She is scheduled to present at 7:00 p.m. ET (4:00 p.m. PT). Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and a range of services. Zoetis ...
December 11, 2019
The Board of Directors of Zoetis Inc . (NYSE:ZTS) has declared a first quarter 2020 dividend payable to holders of the company’s common stock of $0.20 per share, an increase of 22% from the quarterly dividend rate paid in 2019. The dividend is to be paid on Tuesday, March 3, 2020, to holders of record on Friday, January 17, 2020. “Zoetis continues to drive revenue growth and increase its financial strength through a diverse and innovative product portfolio that provides solutions across the continuum of animal care,” said Glenn David, Executive Vice President and Chief Financial Officer. “We are well-positioned to generate cash for future growth and value creation opportunities, and I am pleased to announce that we are increasing our dividend by 22% in 2020 as part of our commitment to returning excess capital to shareholders.” About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of ...
November 22, 2019
Zoetis Inc . (NYSE:ZTS) today announced the acquisition of ZNLabs, a full-service veterinary clinical reference laboratory company with a network of labs across the U.S. This follows Zoetis’ recent acquisition of Phoenix Lab as its entry into reference laboratory services and builds on a strategy to develop a more comprehensive diagnostics offering with enhanced value for veterinarians in the U.S. Financial terms of the transaction are not being disclosed. Founded by veterinarians seeking to revolutionize reference laboratory services for companion animals, ZNLabs is guided by its mission to be “Simple. Friendly. Fair.” The company has differentiated itself by offering a simple test menu and fast results with friendly service and no contracts. ZNLabs operates a “hub” laboratory in Louisville, adjacent to a major logistics provider for fast sample turnaround times, with its “spoke” laboratories in Boise, Chicago, Cincinnati, Dallas, New Orleans and Salt Lake City providing local ...
November 7, 2019
Reports Revenue of $1.6 Billion, Growing 7%, and Net Income of $433 Million, or $0.90 per Diluted Share, Increasing 25% and 27%, Respectively, on a Reported Basis for Third Quarter 2019 Reports Adjusted Net Income of $455 Million, or Adjusted Diluted EPS of $0.94, for Third Quarter 2019 Delivers 9% Operational Growth in Revenue and 10% Operational Growth in Adjusted Net Income for Third Quarter 2019 Updates Full Year 2019 Revenue Guidance to $6.200 - $6.250 Billion and Diluted EPS of $2.99 - $3.08 on a Reported Basis, or $3.57 - $3.62 on an Adjusted Basis Zoetis Inc. (NYSE: ZTS) today reported its financial results for the third quarter of 2019 and updated its guidance for full year 2019. The company reported revenue of $1.6 billion for the third quarter of 2019, an increase of 7% compared with the third quarter of 2018. Net income for the third quarter of 2019 was $433 million, or $0.90 per diluted share, an increase of 25% and 27%, respectively, on a reported basis. Adjusted net ...
October 31, 2019
Zoetis Inc . (NYSE:ZTS) today announced the completion of the acquisition of Phoenix Central Laboratory for Veterinarians, Inc. (Phoenix Lab), a full service veterinary reference laboratory company, after fulfilling all closing requirements. With the addition of reference laboratory services, Zoetis now can provide more comprehensive diagnostics products and services as an enhanced value to veterinarians in the U.S. Financial terms of the transaction are not being disclosed. Reference laboratories and point-of-care diagnostic testing are highly synergistic, offering veterinarians a single source for a full spectrum of tests, as well as access to the expertise of Board-certified specialists and pathologists to support test results. Phoenix Lab, founded in 1989 and headquartered near Seattle, serves veterinary clinics in 20 states, primarily in the Pacific Northwest, with complete clinical and anatomic pathology testing as well as microbiology, serology, hematology, chemistry, ...
October 28, 2019
Collaborates with Texas A&M researchers to help reduce the threat of animal disease Brings research jobs to College Station for innovation in livestock animal health COLLEGE STATION, TEXAS, AND PARSIPPANY, NEW JERSEY, October 28, 2019 - Zoetis, the world's leading animal health company, has signed an agreement with Texas A&M University’s Health Science Center for Innovation in Advanced Development and Manufacturing (CIADM) to establish a facility for accelerating the development of transboundary and emerging disease vaccines - including those for Foot-and-Mouth Disease (FMD ), a virus that can cause serious illness in cattle, pigs, and sheep. Working side by side with Zoetis scientists, CIADM staff will collaborate in the development of processes, assays, and formulations used to produce new vaccines. As part of the agreement, Zoetis is setting up a 12,800-square-foot secure, biocontainment lab off-campus utilizing modular cleanroom technology.  The Transboundary and Emerging Disease ...
October 22, 2019
PARSIPPANY, N.J.-( BUSINESS WIRE )- Zoetis Inc. (NYSE:ZTS) will participate in the Credit Suisse 28th Annual Healthcare Conference on Tuesday, Nov. 12, 2019, in Scottsdale, Ariz. Kristin Peck, CEO-elect, Executive Vice President and Group President, U.S. Operations, Business Development and Strategy, and Glenn David, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. They are scheduled to present at 3:15 p.m. ET (1:15 p.m. MT). Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and ...
October 3, 2019
The Board of Directors of Zoetis Inc . (NYSE:ZTS) has declared a fourth quarter 2019 dividend payable to holders of the company’s common stock of $0.164 per share. The dividend is to be paid on Monday, Dec. 2, 2019, to holders of record on Tuesday, Oct. 22, 2019. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2018, the company generated annual revenue of $5.8 billion with approximately 10,000 employees. For more information, visit www.zoetis.com . DISCLOSURE NOTICES Forward-Looking Statements: This press ...
October 3, 2019
Peck currently is Executive Vice President & Group President responsible for U.S. Operations, Business Development and Strategy Alaix to retire as CEO effective December 31, 2019, and will act as advisor on leadership transition through December 31, 2020 Zoetis Inc. (NYSE: ZTS) today announced that Kristin Peck will succeed Juan Ramón Alaix as Chief Executive Officer, effective January 1, 2020, and join the Board of Directors, effective immediately. Alaix, who has been CEO of Zoetis since its formation in 2012, has decided to retire as CEO effective December 31, 2019. He will act as an advisor on the leadership transition through December 31, 2020. Peck currently serves as Executive Vice President and Group President of U.S. Operations, Business Development and Strategy, and she has been a member of the Zoetis executive leadership team since the company’s formation in 2012. She will remain in her current position until the transition is complete on December 31, 2019. “Kristin is the ...
September 30, 2019
Zoetis Inc . (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, Nov. 7, 2019. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Glenn David will review third quarter 2019 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be made available on Nov. 7, 2019. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and a range of services. Zoetis ...
September 24, 2019
Zoetis recognized by Working Mother magazine for its career advancement opportunities, female representation and work-life programs Data Analytics expert Saba Belay named Zoetis’ 2019 Working Mother of the Year PARSIPPANY, N.J.-( BUSINESS WIRE )- Zoetis Inc . (NYSE: ZTS) today announced that it has been named one of Working Mother magazine’s "100 Best Companies for Working Mothers" for the sixth consecutive year. The publication selects the top 100 companies in the U.S. that lead in areas of female representation and advancement, benefits, parental leave, childcare and flexible work arrangements. “We are honored to be building a legacy as a consistent member of Working Mother magazine’s top companies,” said Roxanne Lagano, Executive Vice President, Chief Human Resources Officer and Communications at Zoetis. “This recognition is a testament to the policies, programs and supportive culture we have established at Zoetis. Our colleagues are empowered to take on challenges and experiences ...
September 20, 2019
Gives veterinarians a new choice for the treatment of mixed external and internal parasitic infestations Treats and has persistent efficacy against ticks and fleas for one month Treats gastrointestinal nematodes Prevents heartworm disease (Dirofilaria immitis) and lungworm disease (angiostrongylosis) Zoetis Inc. (NYSE:ZTS) today announced that the European Commission has granted marketing authorisation for Simparica Trio™ (sarolaner/moxidectin/pyrantel) chewable tablets, a once-monthly triple combination antiparasitic medication for dogs with, or at risk from, mixed external and internal parasitic infestations. The granting of the marketing authorisation follows a positive opinion adopted by the Committee for Medicinal Products for Veterinary Use on July 18, 2019. “The approval of Simparica Trio™ provides veterinarians a safe and effective option for the treatment of mixed external and internal parasitic infestations in dogs in the form of a new oral chewable,” said Dr. Domenico ...
September 9, 2019
Zoetis Inc . today announced that its scientists presented positive efficacy data for the company’s investigational, triple combination parasiticide product at the 2019 Triennial meeting of the American Heartworm Society (AHS) in New Orleans, La. Zoetis is developing a triple combination product containing sarolaner, moxidectin and pyrantel that is administered orally once a month as a preventative for heartworm disease and to treat and control ticks, fleas, and intestinal nematodes in dogs. The results from effectiveness studies in dogs treated with the combination product demonstrated that no adult heartworms were recovered from animals in the laboratory studies and no positive test results for adult heartworms were obtained from dogs in the field study. The product was well-tolerated in all studies presented. In addition, data from a separate study, which tested the efficacy of oral moxidectin at doses ranging from 3 to 60 µg/kg against three confirmed macrocyclic lactone resistant ...
September 4, 2019
Zoetis Inc. (NYSE:ZTS) will participate in the Bank of America Merrill Lynch Global Healthcare Conference on Thursday, Sept. 19, 2019, in London, England. Clint Lewis, Executive Vice President and Group President, International Operations, Commercial Development, Global Genetics, Aquatic Health and Human Medical Diagnostics, will represent the company and respond to questions from analysts. He is scheduled to present at 11:10 a.m. ET (4:10 p.m. London time). Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines, medicines ...
August 15, 2019
Expands Point-of-Care diagnostic offerings to deliver more comprehensive equine health care Provides the convenience of a stall-side blood test PARSIPPANY, NEW JERSEY, AUGUST 15, 2019 – Today, Zoetis, the world’s leading animal health company, announced that it will expand its portfolio of products and services for horses with the Stablelab® hand-held, point-of-care diagnostic blood test, which provides veterinarians critical information related to equine inflammation in 10 minutes. The Stablelab hand-held reader detects and quantifies the biomarker Serum Amyloid A (SAA), which is a major, acute phase protein produced by the liver that rapidly and dramatically increases in response to inflammation caused by infection.   By measuring SAA, veterinarians can assess the severity of an infection sooner – often, before clinical symptoms start - and are able to monitor the horse’s response over the course of treatment.1 “Zoetis has always been committed to providing veterinarians and horse ...
August 15, 2019
Zoetis Inc. (NYSE:ZTS) will participate in the Morgan Stanley 17th Annual Global Healthcare Conference on Tuesday, Sept. 10, 2019, in New York, N.Y. Glenn David, Executive Vice President and Chief Financial Officer, and Kristin Peck, Executive Vice President and Group President, U.S. Operations, Business Development and Strategy, will represent the company and respond to questions from analysts. They are scheduled to present at 12:20 p.m. ET. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines, medicines and diagnostics, ...
August 14, 2019
Zoetis Inc. (NYSE: ZTS) today announced the completion of the acquisition of Platinum Performance, a privately-held nutrition-focused animal heath company, after fulfilling all closing requirements. The acquisition was first announced on July 22 and financial terms of the transaction are not being disclosed. “We are pleased to welcome the Platinum Performance team to Zoetis and together expand on the success of their high-quality, nutritional product formulas for horses, dogs and cats,” said Kristin Peck, Executive Vice President and Group President, U.S. Operations, Business Development and Strategy for Zoetis. “We look forward to coupling the expertise of Platinum’s colleagues and strength of the brand in the equine community with Zoetis’ global scale, resources and capabilities to drive increased focus on health and wellness as part of the continuum of animal care.” Platinum Performance was established in 1996 by Dr. Doug Herthel, DVM, and his son Mark Herthel, who will continue to ...
August 6, 2019
Reports Revenue of $1.5 Billion, Growing 9%, and Net Income of $371 Million, or $0.77 per Diluted Share, Decreasing 3%, on a Reported Basis for Second Quarter 2019 Reports Adjusted Net Income of $436 Million, or Adjusted Diluted EPS of $0.90, for Second Quarter 2019 Delivers 14% Operational Growth in Revenue and 17% Operational Growth in Adjusted Net Income for Second Quarter 2019 Raises Full Year 2019 Revenue Guidance to $6.175 - $6.275 Billion and Diluted EPS of $2.93 - $3.04 on a Reported Basis, or $3.53 - $3.60 on an Adjusted Basis Zoetis Inc . (NYSE: ZTS) today reported its financial results for the second quarter of 2019 and raised its guidance for full year 2019. The company reported revenue of $1.5 billion for the second quarter of 2019, an increase of 9% compared with the second quarter of 2018. Net income for the second quarter of 2019 was $371 million, or $0.77 per diluted share, a decrease of 3%, on a reported basis. Adjusted net income 1 for the second quarter of 2019 was ...
July 31, 2019
Zoetis, the leading global animal health company, today announced it is teaming up with actress and animal lover Kate Walsh 1 to help dogs feel their best and stay on their A-Game. The Show Us Your Dog’s A-Game campaign brings awareness to how skin diseases and allergies affect a dog’s well-being, and encourages pet owners to visit their veterinarians who can provide the right treatment to bring back their dogs’ A-Games. Timed with the inaugural “Itchy Pet Awareness Month” in August, Zoetis encourages dog owners to share photos or videos of their dogs’ A-Games on social media using the #MyDogsAGame hashtag. Each post will trigger a $10 donation2 by Zoetis Petcare (a U.S. business unit of Zoetis) to its K-9 Courage Program, which provides healthcare assistance to retired military and police dogs, as well as active service dogs that assist veterans suffering from post-traumatic stress. Posts may also be featured on an interactive gallery on www.MyDogsAGame.com, where dog owners can ...
July 29, 2019
Zoetis targets livestock immunotherapies as alternatives to antibiotics R&D incubator lab at CSU brings livestock health research, jobs to Fort Collins FORT COLLINS, COLORADO, AND PARSIPPANY, NEW JERSEY, July 29, 2019 - Zoetis, the world's leading animal health company, has signed an agreement with Colorado State University (CSU) to establish a research lab at CSU that will explore the livestock immune system and target new immunotherapies – paving the way for new alternatives to antibiotics in food-producing animals. The new 3,000-square-foot Zoetis Incubator Research Lab will operate at the Research Innovation Center on CSU's Foothills Campus starting in early 2020. In this landmark R&D collaboration, Zoetis scientists will be co-located with CSU’s highly skilled scientists, core laboratories, research programs and services to seed innovations for livestock animal health. While the Zoetis Incubator Research Lab will reside within CSU’s Research Innovation Center, it will be part of ...
July 23, 2019
PARSIPPANY, N.J - July 23, 2019 – Zoetis is aware of a video circulating on social media that references Simparica ® (sarolaner) Chewables and a potential neurologic adverse event in a dog in the U.S. Since coming to the attention of Zoetis, the company has offered the following response to inquiries: At Zoetis, we are committed to providing safe and effective products to veterinarians, pet owners and the animals in their care. Many Zoetis colleagues own pets themselves, and we can all sympathize with the frustration and concern that pet owners experience when their pets are sick. We have been in contact with the pet owner in this video to better understand the situation. Simparica is one of four tick and flea medications for dogs in the isoxazoline class currently on the market. The labeling for Simparica is approved by the FDA. The product label and all related promotional materials have always included information about neurologic signs such as tremors, unsteadiness, and/or ...
July 22, 2019
Zoetis Inc. (NYSE: ZTS) today announced it has entered into an agreement to acquire Platinum Performance, a privately held, nutrition-focused animal health company. Platinum’s premium nutritional product formulas and unique approach to the field of scientific wellness for horses, dogs and cats will further strengthen and diversify Zoetis’ portfolio in the equine and petcare markets. Financial terms of the transaction are not being disclosed. Platinum’s flagship equine products include Platinum Performance® Equine, a comprehensive wellness and performance formula, and Platinum Performance® CJ, which delivers wellness and performance with the addition of joint support ingredients. Its petcare products include Platinum Performance® formulations that focus on wellness and joint support for dogs and cats. With the acquisition of Platinum’s premium quality, nutritional formulas, Zoetis is entering this space for horses and building on the company’s existing nutritional portfolio for dogs ...
June 28, 2019
Zoetis Inc . (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, Aug. 6, 2019. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Glenn David will review second quarter 2019 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be made available on Aug. 6, 2019. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and a range of services. Zoetis ...
May 29, 2019
Zoetis Inc. (NYSE:ZTS) will participate in the William Blair 39 th Annual Growth Stock Conference on Thursday, June 6, 2019, in Chicago, Ill. Juan Ramón Alaix, Chief Executive Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 9:00 a.m. ET / 8:00 a.m. CT. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines, medicines and diagnostics, which are complemented by genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and people ...
May 29, 2019
Accelerated efforts in second year of the A.L.P.H.A. initiative Zoetis’ African Livestock Productivity and Health Advancement (A.L.P.H.A.) initiative, which aims to improve livestock health and positively impact farmers’ livelihoods in sub-Saharan Africa, is increasing access to animal health education and infrastructure in its second year. Following the success of A.L.P.H.A. in Uganda, Nigeria and Ethiopia, the initiative was extended by two years, and will now run until 2022. It was also geographically expanded into Tanzania. The initiative has also placed a special emphasis on providing equal access to animal health training for women. “Animal health is extremely important in contributing to sustainable economic development goals and business opportunities in Africa,” said Clint Lewis, EVP and Group President at Zoetis. “Farming and animal agriculture are major forms of livelihood for people in sub-Saharan Africa. By improving access to critical veterinary products and services, ...
May 20, 2019
Zoetis Inc. (NYSE:ZTS) will participate in the Stifel 2019 Dental & Veterinary Conference on Wednesday, May 29, 2019, in New York, N.Y. Clint Lewis, Executive Vice President and Group President, International Operations, Commercial Development, Global Genetics, Aquatic Health and Human Medical Diagnostics will represent the company and respond to questions from analysts. He is scheduled to present at 10:30 a.m. ET. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines, medicines and diagnostics, which are complemented by ...
May 15, 2019
Zoetis Inc . (NYSE:ZTS) today announced the results of shareholder voting at its 2019 Annual Meeting of Shareholders and provided details on its third quarter 2019 dividend. Annual Meeting of Shareholders Zoetis held its annual meeting today in Short Hills, N.J., with Chairman Michael B. McCallister presiding over the business portion of the meeting and shareholder voting. Chief Executive Officer Juan Ramón Alaix discussed the company’s strong performance in 2018 and its strategies for continued growth and market leadership in the global animal health industry. The results of shareholder voting from the meeting were as follows: Juan Ramón Alaix, Paul M. Bisaro, Frank A. D’Amelio and Michael B. McCallister have been elected as directors for three-year terms. Shareholders approved, on an advisory basis, the compensation of the company’s named executive officers. Shareholders ratified and approved the selection of KPMG LLP as the company’s independent registered public accounting firm ...
May 2, 2019
Reports Revenue of $1.5 Billion, Growing 7%, and Net Income of $312 Million, or $0.65 per Diluted Share, Decreasing 11% and 10%, respectively, on a Reported Basis for First Quarter 2019 Reports Adjusted Net Income of $424 Million, or Adjusted Diluted EPS of $0.88, for First Quarter 2019 Delivers 11% Operational Growth in Revenue and 18% Operational Growth in Adjusted Net Income for First Quarter 2019 Updates Full Year 2019 Revenue Guidance to $6.100 - $6.225 Billion and Diluted EPS of $2.79 - $2.93 on a Reported Basis, or $3.42 - $3.52 on an Adjusted Basis Zoetis Inc . (NYSE: ZTS) today reported its financial results for the first quarter of 2019 and updated its guidance for full year 2019. The company reported revenue of $1.5 billion for the first quarter of 2019, an increase of 7% compared with the first quarter of 2018. Net income for the first quarter of 2019 was $312 million, or $0.65 per diluted share, a decrease of 11% and 10%, respectively, on a reported basis. Adjusted net ...
April 17, 2019
Zoetis Inc . (NYSE: ZTS), the global leader in animal health, today announced that it has been named one of America’s Best Midsize Employers by Forbes Magazine for the fourth year in a row, ranking among the top 150 companies. “At Zoetis, we know our people shape our reputation as a great place to work and drive our success,” said Roxanne Lagano, Executive Vice President, Chief Human Resources Officer and Communications. “We are proud of the culture we have at our company, and we are excited that our colleagues and others recommend Zoetis as one of America’s Best Employers.” Forbes determined its America’s Best Employers list based on an independent survey among a sample of 50,000 American employees working for companies with at least 1,000 people in their U.S. operations. The willingness to recommend one's own employer was used as the most important factor in the assessment. The employees were consulted anonymously through online access panels which allowed them to express their ...
March 29, 2019
Zoetis Inc . (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, May 2, 2019. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Glenn David will review first quarter 2019 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be made available on May 2, 2019. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and a range of services. Zoetis serves ...
March 5, 2019
Zoetis Inc . (NYSE: ZTS) today announced that it has been named one of the 2019 Top Companies for Executive Women by the National Association for Female Executives. This honor recognizes U.S. corporations where there is a strong focus on best practices that demonstrate effectiveness in moving women to senior ranks. This is the first year that Zoetis has earned a spot on this prestigious list. “We are honored to be named one of NAFE’s Top Companies for Executive Women for the first time,” said Roxanne Lagano, Executive Vice President, Chief Human Resources Officer and Communications at Zoetis. “We strive to create a workplace where diverse backgrounds and perspectives are valued, and colleagues are empowered to take on challenges and experiences that help them reach their career goals. Our commitment to women’s advancement is illustrated across our executive ranks and in the development opportunities we offer to all our colleagues.” NAFE ranked Zoetis most highly for its workforce ...
February 14, 2019
For Fourth Quarter 2018, Zoetis Reports Revenue of $1.6 Billion, Growing 7%, and Net Income of $345 Million, or $0.71 per Diluted Share, on a Reported Basis Reports Adjusted Net Income of $382 Million, or Adjusted Diluted EPS of $0.79, for Fourth Quarter 2018 Delivers 11% Operational Growth in Revenue and 21% Operational Growth in Adjusted Net Income for Fourth Quarter 2018 For Full Year 2018, Zoetis Reports Revenue of $5.8 Billion, Growing 10%, and Net Income of $1.4 Billion, or $2.93 per Diluted Share, on a Reported Basis Reports Adjusted Net Income of $1.5 Billion, or Adjusted Diluted EPS of $3.13, for Full Year 2018 Delivers 10% Operational Growth in Revenue and 31% Operational Growth in Adjusted Net Income for Full Year 2018 Provides Full Year 2019 Revenue Guidance of $6.175 - $6.300 Billion, with Diluted EPS of $2.83 - $2.99 on a Reported Basis, or $3.42 - $3.52 on an Adjusted Basis Zoetis Inc . (NYSE:ZTS) today reported its financial results for the fourth quarter and full year ...
February 12, 2019
The Board of Directors of Zoetis Inc . (NYSE:ZTS) has declared a second quarter 2019 dividend payable to holders of the company’s common stock of $0.164 per share. The dividend is to be paid on Monday, June 3, 2019, to holders of record on Thursday, April 18, 2019. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2017, the company generated annual revenue of $5.3 billion with approximately 9,000 employees. For more information, visit www.zoetis.com . DISCLOSURE NOTICES Forward-Looking Statements: This press release ...